
John M. Hoffmann
Examiner (ID: 5190, Phone: (571)272-1191 , Office: P/1741 )
| Most Active Art Unit | 1731 |
| Art Unit(s) | 1712, 1731, 1741, 1791, 1304, 1303 |
| Total Applications | 1565 |
| Issued Applications | 722 |
| Pending Applications | 142 |
| Abandoned Applications | 703 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 7650876
[patent_doc_number] => 20110300145
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-12-08
[patent_title] => 'Interferon Alpha Antibodies And Their Uses'
[patent_app_type] => utility
[patent_app_number] => 13/211092
[patent_app_country] => US
[patent_app_date] => 2011-08-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 30425
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 15
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0300/20110300145.pdf
[firstpage_image] =>[orig_patent_app_number] => 13211092
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/211092 | Interferon alpha antibodies and their uses | Aug 15, 2011 | Issued |
Array
(
[id] => 7650884
[patent_doc_number] => 20110300153
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-12-08
[patent_title] => 'ANTIBODY PRODUCED USING OSTRICH AND METHOD FOR PRODUCTION THEREOF'
[patent_app_type] => utility
[patent_app_number] => 13/210516
[patent_app_country] => US
[patent_app_date] => 2011-08-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 6599
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0300/20110300153.pdf
[firstpage_image] =>[orig_patent_app_number] => 13210516
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/210516 | Method of producing anti-CD166 antibody in ostrich | Aug 15, 2011 | Issued |
Array
(
[id] => 7776317
[patent_doc_number] => 20120039895
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-02-16
[patent_title] => 'PHOSPHORYCHOLINE CONJUGATES AND CORRESPONDING ANTIBODIES'
[patent_app_type] => utility
[patent_app_number] => 13/208138
[patent_app_country] => US
[patent_app_date] => 2011-08-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 8755
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0039/20120039895.pdf
[firstpage_image] =>[orig_patent_app_number] => 13208138
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/208138 | PHOSPHORYCHOLINE CONJUGATES AND CORRESPONDING ANTIBODIES | Aug 10, 2011 | Abandoned |
Array
(
[id] => 8903660
[patent_doc_number] => 20130171163
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2013-07-04
[patent_title] => 'Inhibition of LAR Phosphatase to Enhance Therapeutic Angiogenesis'
[patent_app_type] => utility
[patent_app_number] => 13/813964
[patent_app_country] => US
[patent_app_date] => 2011-08-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 20
[patent_no_of_words] => 30406
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13813964
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/813964 | Inhibition of LAR Phosphatase to Enhance Therapeutic Angiogenesis | Aug 4, 2011 | Abandoned |
Array
(
[id] => 7754469
[patent_doc_number] => 20120027686
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-02-02
[patent_title] => 'HK1-BINDING PROTEINS'
[patent_app_type] => utility
[patent_app_number] => 13/192786
[patent_app_country] => US
[patent_app_date] => 2011-07-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 54297
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0027/20120027686.pdf
[firstpage_image] =>[orig_patent_app_number] => 13192786
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/192786 | HK1-BINDING PROTEINS | Jul 27, 2011 | Abandoned |
Array
(
[id] => 8174222
[patent_doc_number] => 20120108797
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-05-03
[patent_title] => 'TARGETED BINDING AGENTS DIRECTED TO UPAR AND USES THEREOF'
[patent_app_type] => utility
[patent_app_number] => 13/193167
[patent_app_country] => US
[patent_app_date] => 2011-07-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 47416
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0108/20120108797.pdf
[firstpage_image] =>[orig_patent_app_number] => 13193167
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/193167 | TARGETED BINDING AGENTS DIRECTED TO UPAR AND USES THEREOF | Jul 27, 2011 | Abandoned |
Array
(
[id] => 9977039
[patent_doc_number] => 09023346
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2015-05-05
[patent_title] => 'Method of treating stroke with tenecteplase'
[patent_app_type] => utility
[patent_app_number] => 13/189413
[patent_app_country] => US
[patent_app_date] => 2011-07-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 3
[patent_no_of_words] => 10567
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13189413
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/189413 | Method of treating stroke with tenecteplase | Jul 21, 2011 | Issued |
Array
(
[id] => 7662736
[patent_doc_number] => 20110312005
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-12-22
[patent_title] => 'Enzymatic modification of cell-surface H antigen by glycosyltransferases'
[patent_app_type] => utility
[patent_app_number] => 13/137096
[patent_app_country] => US
[patent_app_date] => 2011-07-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7263
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0312/20110312005.pdf
[firstpage_image] =>[orig_patent_app_number] => 13137096
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/137096 | Enzymatic modification of cell-surface H antigen by glycosyltransferases | Jul 19, 2011 | Abandoned |
Array
(
[id] => 7733275
[patent_doc_number] => 20120015867
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-01-19
[patent_title] => 'THERAPEUTIC PEPTIDES AND METHOD'
[patent_app_type] => utility
[patent_app_number] => 13/181323
[patent_app_country] => US
[patent_app_date] => 2011-07-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 18
[patent_no_of_words] => 22575
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0015/20120015867.pdf
[firstpage_image] =>[orig_patent_app_number] => 13181323
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/181323 | Therapeutic TREM-1 peptides | Jul 11, 2011 | Issued |
Array
(
[id] => 8138559
[patent_doc_number] => 20120093818
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-04-19
[patent_title] => 'ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)'
[patent_app_type] => utility
[patent_app_number] => 13/174423
[patent_app_country] => US
[patent_app_date] => 2011-06-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 153
[patent_figures_cnt] => 153
[patent_no_of_words] => 78137
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13174423
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/174423 | Monoclonal antibodies to proprotein convertase subtilisin kexin type 9 (PCSK9) | Jun 29, 2011 | Issued |
Array
(
[id] => 11794132
[patent_doc_number] => 09403882
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2016-08-02
[patent_title] => 'Sulfation of Wnt pathway proteins'
[patent_app_type] => utility
[patent_app_number] => 13/170634
[patent_app_country] => US
[patent_app_date] => 2011-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 21627
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13170634
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/170634 | Sulfation of Wnt pathway proteins | Jun 27, 2011 | Issued |
Array
(
[id] => 8335129
[patent_doc_number] => 20120201835
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-08-09
[patent_title] => 'ANTIBODIES SPECIFIC FOR DKK-1'
[patent_app_type] => utility
[patent_app_number] => 13/169523
[patent_app_country] => US
[patent_app_date] => 2011-06-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 21
[patent_no_of_words] => 20513
[patent_no_of_claims] => 47
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13169523
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/169523 | ANTIBODIES SPECIFIC FOR DKK-1 | Jun 26, 2011 | Abandoned |
Array
(
[id] => 7731537
[patent_doc_number] => 20120014952
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-01-19
[patent_title] => 'COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT MODULATORS'
[patent_app_type] => utility
[patent_app_number] => 13/162479
[patent_app_country] => US
[patent_app_date] => 2011-06-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 31
[patent_no_of_words] => 37131
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0014/20120014952.pdf
[firstpage_image] =>[orig_patent_app_number] => 13162479
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/162479 | COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT MODULATORS | Jun 15, 2011 | Abandoned |
Array
(
[id] => 7733288
[patent_doc_number] => 20120015872
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-01-19
[patent_title] => 'COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT MODULATORS'
[patent_app_type] => utility
[patent_app_number] => 13/162434
[patent_app_country] => US
[patent_app_date] => 2011-06-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 31
[patent_no_of_words] => 37438
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0015/20120015872.pdf
[firstpage_image] =>[orig_patent_app_number] => 13162434
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/162434 | Complement receptor 1 and 2 fusion proteins | Jun 15, 2011 | Issued |
Array
(
[id] => 7733287
[patent_doc_number] => 20120015871
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-01-19
[patent_title] => 'COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT MODULATORS'
[patent_app_type] => utility
[patent_app_number] => 13/162423
[patent_app_country] => US
[patent_app_date] => 2011-06-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 31
[patent_no_of_words] => 37129
[patent_no_of_claims] => 32
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0015/20120015871.pdf
[firstpage_image] =>[orig_patent_app_number] => 13162423
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/162423 | COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT MODULATORS | Jun 15, 2011 | Abandoned |
Array
(
[id] => 8065929
[patent_doc_number] => 20110244053
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-10-06
[patent_title] => 'Use a goat serum for veterinary treatment'
[patent_app_type] => utility
[patent_app_number] => 13/134512
[patent_app_country] => US
[patent_app_date] => 2011-06-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2832
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0244/20110244053.pdf
[firstpage_image] =>[orig_patent_app_number] => 13134512
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/134512 | Use a goat serum for veterinary treatment | Jun 8, 2011 | Abandoned |
Array
(
[id] => 9008941
[patent_doc_number] => 08524235
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2013-09-03
[patent_title] => 'Method for treating coronary artery disease using antibody binding human protein tyrosine phosphatase beta(HPTPbeta)'
[patent_app_type] => utility
[patent_app_number] => 13/115180
[patent_app_country] => US
[patent_app_date] => 2011-05-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 13334
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13115180
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/115180 | Method for treating coronary artery disease using antibody binding human protein tyrosine phosphatase beta(HPTPbeta) | May 24, 2011 | Issued |
Array
(
[id] => 8791666
[patent_doc_number] => 20130108635
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2013-05-02
[patent_title] => 'METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF MATRIX MINERALIZATION DISORDERS'
[patent_app_type] => utility
[patent_app_number] => 13/695127
[patent_app_country] => US
[patent_app_date] => 2011-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 17
[patent_no_of_words] => 19991
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13695127
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/695127 | Methods, compositions, and kits for the treatment of matrix mineralization disorders | Apr 28, 2011 | Issued |
Array
(
[id] => 8903650
[patent_doc_number] => 20130171153
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2013-07-04
[patent_title] => 'PROTEINS THAT BIND PI16 AND USES THEREOF'
[patent_app_type] => utility
[patent_app_number] => 13/640356
[patent_app_country] => US
[patent_app_date] => 2011-04-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 56
[patent_figures_cnt] => 56
[patent_no_of_words] => 49439
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 9
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13640356
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/640356 | Proteins that bind PI16 and uses thereof | Apr 17, 2011 | Issued |
Array
(
[id] => 7650891
[patent_doc_number] => 20110300160
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-12-08
[patent_title] => 'SULFATION OF WNT PATHWAY PROTEINS'
[patent_app_type] => utility
[patent_app_number] => 13/088059
[patent_app_country] => US
[patent_app_date] => 2011-04-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 18049
[patent_no_of_claims] => 92
[patent_no_of_ind_claims] => 12
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0300/20110300160.pdf
[firstpage_image] =>[orig_patent_app_number] => 13088059
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/088059 | Antibodies specific for sulfated sclerostin | Apr 14, 2011 | Issued |